# Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

> **NCT05718297** · PHASE2 · WITHDRAWN · sponsor: **ETOP IBCSG Partners Foundation**

## Conditions studied

- NSCLC, Stage III
- ALK-rearrangement

## Interventions

- **DRUG:** Brigatinib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05718297
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-07
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Despite our efforts, the trial faced challenges like a longer activation period and slower accrual. We proposed a redesign, but TAKEDA withdrew. As a non-profit organisation, we can't continue without TAKEDA's support and must discontinue the trial.
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718297, "Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05718297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*